263 related articles for article (PubMed ID: 29514186)
1. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
[TBL] [Abstract][Full Text] [Related]
2. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.
Dirice E; Walpita D; Vetere A; Meier BC; Kahraman S; Hu J; Dančík V; Burns SM; Gilbert TJ; Olson DE; Clemons PA; Kulkarni RN; Wagner BK
Diabetes; 2016 Jun; 65(6):1660-71. PubMed ID: 26953159
[TBL] [Abstract][Full Text] [Related]
4. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
6. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.
Wang P; Alvarez-Perez JC; Felsenfeld DP; Liu H; Sivendran S; Bender A; Kumar A; Sanchez R; Scott DK; Garcia-Ocaña A; Stewart AF
Nat Med; 2015 Apr; 21(4):383-8. PubMed ID: 25751815
[TBL] [Abstract][Full Text] [Related]
7. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
[TBL] [Abstract][Full Text] [Related]
8. Novel factors modulating human β-cell proliferation.
Shirakawa J; Kulkarni RN
Diabetes Obes Metab; 2016 Sep; 18 Suppl 1(Suppl 1):71-7. PubMed ID: 27615134
[TBL] [Abstract][Full Text] [Related]
9. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
[TBL] [Abstract][Full Text] [Related]
10. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
11. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
[TBL] [Abstract][Full Text] [Related]
12. Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells.
Wang P; Karakose E; Liu H; Swartz E; Ackeifi C; Zlatanic V; Wilson J; González BJ; Bender A; Takane KK; Ye L; Harb G; Pagliuca F; Homann D; Egli D; Argmann C; Scott DK; Garcia-Ocaña A; Stewart AF
Cell Metab; 2019 Mar; 29(3):638-652.e5. PubMed ID: 30581122
[TBL] [Abstract][Full Text] [Related]
13. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis.
Barzowska A; Pucelik B; Pustelny K; Matsuda A; Martyniak A; Stępniewski J; Maksymiuk A; Dawidowski M; Rothweiler U; Dulak J; Dubin G; Czarna A
Cells; 2021 Aug; 10(9):. PubMed ID: 34571911
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in Cancer Cell Dormancy.
MacDonald J; Ramos-Valdes Y; Perampalam P; Litovchick L; DiMattia GE; Dick FA
Mol Cancer Res; 2017 Apr; 15(4):371-381. PubMed ID: 28031411
[TBL] [Abstract][Full Text] [Related]
15. DYRK1A Controls HIV-1 Replication at a Transcriptional Level in an NFAT Dependent Manner.
Booiman T; Loukachov VV; van Dort KA; van 't Wout AB; Kootstra NA
PLoS One; 2015; 10(12):e0144229. PubMed ID: 26641855
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) by dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Song WJ; Song EA; Jung MS; Choi SH; Baik HH; Jin BK; Kim JH; Chung SH
J Biol Chem; 2015 Jan; 290(4):2321-33. PubMed ID: 25477508
[TBL] [Abstract][Full Text] [Related]
20. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
